Bone marrow transplantation (BMT) has become an increasingly common option for management of oncologic and other conditions in recent years. BMT involves the use of preconditioning regimens that compromise fertility. Many conditioning regimens have devastating effects on the spermatogonial stem cell pool, leading to lack of functional gametes and consequent sterility. BMT is usually undertaken as an urgent or semi-urgent procedure, either as a primary modality of cancer care for high-risk leukaemias, after failed chemotherapy or relapse of leukaemia, or less commonly in the setting of immune deficiency syndromes or bone marrow failures such as aplastic anaemia. 1 Occasionally for conditions such as thalassemia major, or aplastic anaemia, it is possible to plan BMT within a longer time frame, wherein blood transfusions continue but marrow failure predicates a need for further management.
In adult men or in late peripubertal and postpubertal adolescent males, cryopreservation of ejaculated sperm or sperm obtained by testicular biopsy can provide assurance of an option for future fertility, prior to gonadotoxic treatments. This strategy is not available for prepubertal boys because spermatogenesis does not occur prior to puberty. Spermatogonial cell lines are present in the testes at birth. Foetal and postnatal gonocyte differentiation to spermatogonia occurs progressively. Sertoli cells mature during childhood, germ cells proliferate, then seminiferous tubule outgrowth occurs in adolescence, with onset of spermatogenesis sometime between ages 12 and 15 years. 2 Delayed puberty and hypogonadism are common in children with beta thalassemia major, due both to chronic disease and to transfusion requirements. Despite chelation programmes, chronic iron overload remains a management challenge for many patients and their physicians. In addition to iron deposition in many other organs, the pituitary gland and, less commonly, the testes are targets for iron overload, with hypogonadism well recognized as a complication of repeated blood transfusions. 3 In addition, most chronic diseases are sufficiently debilitating, resulting in pubertal delay, which may require intervention in the form of pubertal induction and hormonal support to complete normal linear growth and virilization in a boy or feminization in a girl.
We describe the use of human chorionic gonadotrophin (hCG), with later addition of follicle stimulating hormone (FSH) in a 13-year-old boy with beta thalassemia major, one of two affected children in a family of three boys and two girls. Prior to bone marrow transplant being planned within 12-15 months from the time of first endocrine consultation, the boy of age 12.2 years was referred by his oncology team for discussion of possible fertility preservation options. He had received regular blood transfusions every 3 weeks from age 2.5 years and had a history of suboptimal chelation for several years, with a current ferritin level of 5450 mcg/L (NR o370). He was prepubertal, with 2 mL testes bilaterally and with a height of 151.9 cm (50th centile) in a family with a mid-parental expectation on the 90th centile. His growth chart is shown in Figure 1 .
Discussion of fertility salvage options was undertaken, including the likelihood that conditioning treatment with alkylating agents prior to transplant would result in loss of all germ cells, with consequent sterility. The options were either to undertake testicular biopsy of his prepubertal 2 mL testes, hoping to obtain some spermatogonial cell lines (SCC) to be frozen for possible future maturation, 2 or to induce puberty and hope to obtain spermatogenesis, over a short time span, prior to transplant. The former option is currently entirely experimental in humans, although live progeny have resulted from similar procedures in murine and simian (rhesus macaque) species. 4, 5 Conversely, both semen storage and, if that failed, post-pubertal testicular biopsy offer realistic hope of future fertility in the postpubertal male.
After discussion with the family, the boy and his parents chose the option of pubertal induction. Initially he was followed clinically for 8 months, during which he remained prepubertal with 2 mL testes bilaterally. Bone age was 13 years at a chronologic age of 13 years. BMT was scheduled to take place within 6-9 months. Pubertal induction was commenced, using hCG 500 U twice per week by subcutaneous injection and increasing to 1000 U twice weekly after 3 months. Pubertal progress was mildly accelerated and linear growth rate improved. When serum testosterone reached an adult level of 11.9 nmol/L, FSH 150 IU × 3/week was added for induction of spermatogenesis and increased after 3 months to 300 U thrice weekly. Over 9 months he grew 17.5 cm, with a height achieved of 169.4 cm (50-75th centile). Adult virilization was present, with 20 mL testes bilaterally. Plasma testosterone was 17.6 nmol/L (NR 12-24), Inhibin B 135 ng/L (NR 50-350). Semen collection was performed 9 months after commencement of FSH, with 0.5-1.8 million/mL on three samples and cryopreservation of 11 straws. Four months after semen collection he underwent BMT, preceded by busulphan conditioning.
This report provides the first evidence of feasibility of inducing puberty and spermatogenesis adequate for future fertility, in a young prepubertal adolescent male, prior to BMT. Fertility preservation in this case is assured. Until recently, gonadotoxic treatments that included high-dose alkylating agents in boys and peripubertal adolescent males were almost inevitably accompanied by future infertility. 6 Early reports of successful spermatogonial cell line salvage in mice, with later maturation, fertilization and live progeny resulting have been followed by similar success in monkeys. 4, 5 SCC salvage in prepubertal boys has been performed for more than 14 years and many centres are now considering or offering this option. However, it remains experimental at this time, with no live births reported to date.
A limited window of opportunity exists for inducing puberty in a boy of 12-16 years, if time permits prior to gonadotoxin exposure. Pubertal induction with gonadotrophins is a safe, well-established technique, used for pubertal induction in boys with congenital or childhood-onset hypothalamic hypogonadism. hCG is required for initiation and continuation of intra-testicular testosterone levels that are a prerequisite for supporting spermatogenesis. Successful spermatogenesis is almost always achieved within 6-9 months of addition of FSH in these adolescent males. 7 The only drawback of inducing puberty rapidly, as was undertaken for this boy, is rapid bone age advance with potential reduction in final height achieved. However, BMT with attendant peri-transplant illness and multiple immunosuppressive agent use over months is also likely to have an adverse effect on pubertal progress and final height. This needs to be balanced against the success of fertility preservation.
The option of pubertal induction with gonadotrophins should be considered in future, for other adolescent males, prior to gonadotoxic treatments, to ensure preservation of future fertility. Letter to the Editor
